News

This phase III trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Evamist. The primary endpoint is the reduction in the frequency

The single-dose phase II clinical trial will be conducted at hospitals in Massachusetts and California and is expected to enroll up to 150 patients with C difficile associated

In the collaboration with Arch, Codexis will apply its novel, cost-effective Molecular-Breeding technology to manufacture an undisclosed pharmaceutical compound. In the collaboration with Matrix, Codexis is to develop

tgAAC94 utilizes Targeted Genetics’ Adeno-Associated Viral (AAV) vector technology to deliver a DNA sequence encoding an inhibitor of TNF-alpha, a potent pro-inflammatory cytokine that plays a major role

Orphan products development grants are awarded by the FDA to encourage clinical development of products for use in rare diseases or conditions, usually defined as affecting less than

Valortim is a fully human antibody developed by Medarex’s UltiMAb human antibody development system that targets the bacillus anthracis protective antigen. The research, presented at the Infectious Diseases

MPC-0920 is an orally available, direct thrombin inhibitor. It is designed to address the clinical needs for rapid and predictable anticoagulant action, an improved therapeutic window, predictable patient

CoFactor is Adventrx’s biomodulator designed to enhance the effects and reduce associated toxicity of the widely used cancer drug, 5-fluorouracil (5-FU). The company began dosing patients in the

A second collaboration agreement between TorreyPines and Eisai was signed in February of this year to support the discovery of small molecules that lower A-beta42, a peptide involved